[Antithrombotic action of benzydamine]

Area of Science:

• Pharmacology
• Thrombosis Research

Context:

• Non-steroidal anti-inflammatory drugs (NSAIDs) are widely used for their anti-inflammatory and analgesic properties.
• The antithrombotic potential of NSAIDs is often linked to their inhibition of the cyclooxygenase (COX) pathway.

Purpose:

• To investigate the antithrombotic properties of benzydamine.
• To determine the mechanism of action underlying benzydamine's potential antithrombotic effects, specifically its involvement with the cyclooxygenase pathway.

Summary:

• Benzydamine demonstrated inhibition of rat platelet aggregation in vitro and significantly reduced venous thrombosis in vivo following oral administration.
• Unlike classical NSAIDs such as indomethacin, benzydamine did not influence malondialdehyde formation in dog platelets, suggesting its antithrombotic activity is not mediated by cyclooxygenase inhibition.
• In vivo studies showed minimal inhibition of pulmonary thromboembolism in mice, further supporting the non-involvement of the cyclooxygenase pathway.

Impact:

• These findings reveal that benzydamine possesses distinct antithrombotic properties in vivo.
• The study highlights a novel mechanism of antithrombotic action for benzydamine, independent of cyclooxygenase inhibition.
• Benzydamine represents a potential therapeutic agent for thrombotic conditions with a mechanism distinct from traditional NSAIDs.